Berenberg Bank analyst Caroline Palomeque maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $8.03.
Palomeque covers the Healthcare sector, focusing on stocks such as Halozyme, Anavex Life Sciences, and Ocular Therapeutix. According to TipRanks, Palomeque has an average return of -13.4% and a 28.00% success rate on recommended stocks.
Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $50.67, which is a 531.01% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $54.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Anavex Life Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.11 million. In comparison, last year the company had a GAAP net loss of $12.37 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More on AVXL:
- Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
- Anavex reports Q3 EPS (14c), consensus (17c)
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
- Anavex reports publication of ANAVEX 3-71 in clinical journal
- AVXL Earnings this Week: How Will it Perform?
